Literature DB >> 3953727

Prognostic factors in choroidal and ciliary body melanomas with extrascleral extension.

J M Pach, D M Robertson, B S Taney, J A Martin, R J Campbell, P C O'Brien.   

Abstract

In a retrospective study, 50 (8.2%) of 610 patients with malignant melanoma of the ciliary body or choroid had extrascleral extension. Of 46 patients for whom follow-up data were available, 24 (52%) survived five years, 20 (42%) survived ten years, and 17 (37%) survived 15 years. Factors that seemed to affect survival significantly included intraocular tumor size and extraocular tumor size and location. Our observations did not support the role of primary exenteration. Five patients (11%) with extrascleral extension had orbital recurrences and all died within 31 months of surgery regardless of treatment.

Entities:  

Mesh:

Year:  1986        PMID: 3953727     DOI: 10.1016/0002-9394(86)90828-7

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  9 in total

1.  Orbital exenteration: a 13 year Manchester experience.

Authors:  I Rahman; A E Cook; B Leatherbarrow
Journal:  Br J Ophthalmol       Date:  2005-10       Impact factor: 4.638

2.  Enucleation combined with orbital implants for malignant melanoma of the uvea.

Authors:  J Sassmannshausen; N Bornfeld; A Kluge; W Sauerwein; F Härting; A Wessing
Journal:  Int Ophthalmol       Date:  1989-07       Impact factor: 2.031

3.  Mortality following exenteration for malignant tumours of the orbit.

Authors:  I Rahman; A Maino; A E Cook; B Leatherbarrow
Journal:  Br J Ophthalmol       Date:  2005-11       Impact factor: 4.638

4.  Uveal Melanoma with Massive Extraocular Extension through the Sclerocorneal Limbus.

Authors:  Hyerin Jeong; Ho-Seok Sa
Journal:  Korean J Ophthalmol       Date:  2015-08

5.  Choroidal melanoma with massive extraocular extensions through sclera.

Authors:  Motoki Kimura; Nahoko Ogata; Chieko Shima; Kanji Takahashi
Journal:  Clin Ophthalmol       Date:  2012-12-13

Review 6.  Uveal melanoma: estimating prognosis.

Authors:  Swathi Kaliki; Carol L Shields; Jerry A Shields
Journal:  Indian J Ophthalmol       Date:  2015-02       Impact factor: 1.848

7.  Factors related to survival outcomes following orbital exenteration: a retrospective, comparative, case series.

Authors:  Orapan Aryasit; Passorn Preechawai; Chakree Hirunpat; Orasa Horatanaruang; Penny Singha
Journal:  BMC Ophthalmol       Date:  2018-07-28       Impact factor: 2.209

8.  Current molecular and clinical insights into uveal melanoma (Review).

Authors:  Matteo Fallico; Giuseppina Raciti; Antonio Longo; Michele Reibaldi; Vincenza Bonfiglio; Andrea Russo; Rosario Caltabiano; Giuseppe Gattuso; Luca Falzone; Teresio Avitabile
Journal:  Int J Oncol       Date:  2021-03-02       Impact factor: 5.650

9.  DNA ploidy and S-phase fraction as prognostic factors in patients with uveal melanomas.

Authors:  M Karlsson; B Boeryd; J Carstensen; B Kågedal; S Wingren
Journal:  Br J Cancer       Date:  1995-01       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.